Metanephric adenoma (MA) is a rare benign renal neoplasm that shares morphologic and immunophenotypic overlap with epithelial-predominant Wilms tumor (e-WT) and with the solid variant of papillary renal cell carcinoma (s-PRCC). Cadherin 17 (CDH17) is expressed primarily in the normal intestine and digestive tract tumors and has not been detected in tumors from other sites including the kidney. We investigated the diagnostic utility of CDH17 in differentiating between MA, e-WT, and s-PRCC. Immunohistochemical analysis for CDH17, CD57, AMACR, WT-1, and CDX2 was performed on 17 e-WTs, 15 s-PRCCs, and 21 MAs and assessed on the basis of a combined score of extent and intensity. Normal adult kidney parenchyma was negative for CDH17 staining. CDH17 was expressed in the late stages of fetal kidney development at the junction of the glomerular space and proximal nephron. The majority of MAs (81%) demonstrated membranous CDH17 immunoreactivity in all components (acinar, tubular, and papillary), whereas all cases of e-WTs and s-PRCCs were negative (P < 0.0001). WT-1 was negative in s-PRCC and was positive in all cases of e-WT and MA. All MAs were strongly positive for CD57; however, this marker was also moderate to strongly positive in 6 (35%) e-WTs and 2 (13%) s-PRCCs. AMACR was strongly positive in all s-PRCCs, but moderate reactivity was seen in 3 (17%) e-WTs and 2 MAs (10%). CDH17 is a sensitive (81%) and highly specific (100%) marker for MA and should be considered in the im-munohistochemistry panel for distinguishing MA from its mimics.
M etanephric adenoma (MA) is a rare benign neoplasm of the kidney that is composed of tightly packed, highly cellular, small uniform epithelial cells forming acini, tubules, solid sheets, and papillary structures. [1] [2] [3] MAs may contain glomeruloid bodies resembling abortive papillae and often nuclear grooves and psammoma bodies. The morphologic features of MA often overlap with epithelial-predominant Wilms tumor (e-WT) and with the solid variant of papillary renal cell carcinoma type 1 (s-PRCC). [4] [5] [6] [7] [8] It is important to differentiate MA from e-WT and s-PRCC, as the latter are malignant neoplasms that may require aggressive treatment.
Currently, immunohistochemistry (IHC) is the most useful ancillary technique that helps distinguish between MA and its mimics. MAs are usually diffusely positive for WT-1 and CD57 and typically negative for a-methylacyl CoA racemase (AMACR). 4, 7, 8 These markers are helpful in distinguishing MA from e-WT and s-PRCC, but in some cases the diagnosis may be challenging, as there is overlap in the immunophenotype of these tumors.
The cadherin superfamily of transmembrane glycoproteins are calcium-dependent cell adhesion molecules that demonstrate high tissue-specific expression. 9 Expression of epithelial cadherin (E-CDH, CDH1), neural cadherin (N-CDH, CDH2), kidney-specific cadherin (KSC, CDH16), cadherin 6 (CDH6), cadherin 8 (CDH8), and cadherin 11 (CDH11) has been described in normal and neoplastic kidney. [10] [11] [12] [13] [14] [15] [16] [17] [18] Cadherin 17 (CDH17), also known as liver-intestine cadherin, is expressed in the normal small and large intestinal epithelium, normal pancreatic ducts, and in tumors originating from the digestive system, including colorectal, gastric, and pancreatobiliary adenocarcinomas and hepatocellular carcinoma. [19] [20] [21] [22] [23] Although expression of CDH17 was demonstrated in the developing kidney of zebrafish, 24 CDH17 was not found to be expressed in normal human kidney 20 or renal cell carcinoma, including clear cell, chromophobe, collecting duct, and papillary renal cell carcinoma. 20, 21, 23 On the basis of structural homology of CDH17 to kidney-specific cadherin (CDH16), 13, 14, 25 we hypothesized that CDH17 may also be expressed in some histologic subtypes of kidney tumors.
Our goal in this study was to characterize the expression pattern of CDH17 in MA and to determine whether CDH17 expression may be useful in distinguishing MA from e-WT and s-PRCC.
MATERIALS AND METHODS
Archival cases of MA (4 cases), e-WT (17 cases), and s-PRCC (15 cases) were collected between the years of 1998 and 2013 from the archives of the Departments of Pathology at the Rhode Island Hospital and The Miriam Hospital. In addition, 17 cases of MA were retrieved from the archives of the Department of Pathology at Cleveland Clinic, Cleveland, OH. Six cases of e-WT contained foci of nephrogenic rests. Human fetal kidney tissues from 10-, 17-, and 38-week fetuses and 7-week and 8-monthold infants were also examined. The original hematoxylin and eosin sections were reviewed by 2 pathologists (E.Y. and S.M). Diagnoses were confirmed by histological rereview and supported by adjunctive IHC for WT-1, CD57, and AMACR in all cases.
Tissue Microarray Construction
Tissue microarrays (TMAs) were constructed from 4 MAs, 17 e-WTs, and 15 s-PRCCs. Paraffin blocks containing representative tumor areas were identified on the basis of review of the corresponding hematoxylin and eosin-stained sections. Areas of interest were identified and marked on the source block. The source block was cored, and a 1-mm core was transferred to the recipient "master block" using the Beecher Tissue Microarrayer (Beecher Instruments, Silver Spring, MD). Four representative cores of tumor and 2 cores of normal kidney tissue were arrayed per specimen.
IHC Staining
IHC staining of all MAs, e-WTs, and s-PRCCs for CDH17 was performed on whole tissue sections. Staining for other markers was done on TMAs. Consecutive sections from paraffin-embedded tissue blocks were cut at 4 mm, deparaffinized, and rehydrated with xylene and graded alcohols. IHC staining for CDH17 was performed with the Ventana Discovery system using the DAB MAP detection kit (Ventana Medical Systems, Tucson, AZ). Epitope retrieval was performed in high-pH buffer. A rabbit monoclonal antibody (Ab) SP183 against CDH17 from Cell Marque (Rocklin, CA) was used at a 1:100 dilution as the primary Ab. Sections of normal human colon and small intestine were used as positive controls. IHC staining for WT-1, CD57, AMACR, and CDX2 was performed for all cases using the Dako Autostainer Link 48 (Dako, Carpinteria, CA) and EnVision Dual Link or EnVision Flex detection system (Dako) with DAB (Dako). Appropriate positive and negative controls were stained in parallel. Antibodies, their sources, antigen retrieval, and dilutions are presented in Table 1 .
Staining results were assessed by 2 pathologists (E.Y. and Z.G.) in a blinded manner (without knowing a diagnosis). Immunoreactivity was assessed on the basis of a combined score of the extent and intensity of staining as described previously. 26 Scores 0 to 3 were assigned according to the percentage of positive tumor cells (0 = < 5%, 1 = 5% to 25%; 2 = 25% to 50%; and 3 = > 50%). In positive cases, the staining intensity was scored as strong (3+) when immunoreactivity was easily detectable at low magnification ( Â 40), as moderate (2+) when the staining was visible at Â 100 magnification, or as weak (1+) when the staining was seen at higher-power magnifications (Â 200 and Â 400) but not clearly observed at lower magnifications. The 2 scores were multiplied to give an overall score of 0 to 9, of which 0 was considered negative, 1 to 2 was considered weak, 3 to 6 moderate, and 9 strong staining. Any discordant scores were reviewed together by both scorers to obtain a consensus score.
Statistical Analysis
All statistical analyses were performed using the SAS software, JMP Base version 8.0.0 (SAS, Cary, NC). Association between CDH17, WT-1, CD57, and AMACR expressions and the histologic subtypes of renal tumors was evaluated using the w 2 test. P-values of <0.05 were considered as statistically significant.
RESULTS

CDH17 Expression in MAs, e-WT, and s-PRCC
Microscopically, all MAs were highly cellular tumors composed of small uniform epithelial cells arranged in tightly packed acini, tubules, solid sheets, and papillary structures ( Fig. 1A) . Some MAs contained glomeruloid bodies, resembling abortive papillae, and psammoma calcifications. Wilms tumors were of favorable histology and had a triphasic growth pattern, with the epithelialpredominant component (e-WT) composed of tightly packed cells arranged in tubular structures, occasional glomeruloid bodies, and psammomatous calcifications (Fig. 1B) . s-PRCCs contained tightly packed cells growing in solid sheets, ill-defined tubular patterns, and glomeruloid bodies, similar histologically to those of MAs and e-WT (Fig. 1C) .
The results of the IHC stains for CDH17 (whole tissue sections), CD57, AMACR, and WT-1 (TMAs) are summarized in Table 2 and Figures 2 and 3 . Normal adult kidney parenchyma was negative for CDH17 staining. The majority of MAs (81%) demonstrated CDH17 immunoreactivity, whereas all cases of e-WTs and s-PRCCs were negative (P < 0.0001, Table 2 ). The extent of CDH17 varied from patchy to diffuse, and even in cases with diffuse strong immunoreactivity the staining was not complete in all tumor cells ( Fig. 2A ). Twelve of 17 (71%) positive MAs exhibited moderate to strong CDH17 expression. In 5 MA cases CDH17 showed overall weak staining on the basis of a focal patchy distribution of staining (extent 1+) with moderate intensity (2+). CDH17 expression was seen in a membranous staining pattern with lateral intercellular border accentuation (Fig. 2C) , and immunoreactivity was observed in all components of MAs (acinar, papillary, and Positive nuclear staining with WT-1 was seen in the podocytes of normal renal glomeruli, all cases of e-WT, and all MAs but absent in all s-PRCCs included in our study (Fig. 3 ). CD57 was expressed in the proximal tubules in normal kidney. Strong positive staining for CD57 was seen in all MAs, whereas moderate to strong positivity was observed in 6 (35%) e-WTs and 2 (13%) s-PRCCs ( Fig. 3 , Table 2 ). AMACR expression in the form of strong cytoplasmic positive staining was seen in the proximal tubules of normal kidneys and all s-PRCCs, but moderate immunoreactivity was seen in 3 (17%) e-WTs and 2 (10%) MAs (Fig. 3 , Table 2 ).
CDH17 Expression in Nephrogenic Rests and Fetal Kidneys
One of 6 cases of nephrogenic rests expressed CDH17 (Fig. 4A ), 4 of 6 cases were immunoreactive for WT-1, focally for CD57, and all were negative for AMACR and CDX2 (Figs. 4B-D) .
Fetal kidneys at 10 and 17 weeks gestational age were negative for CDH17 (Fig. 5B) ; however, immunoreactivity was seen in the proximal tubule immediately adjacent to the glomeruli and focally extending to the parietal epithelium of the Bowman capsule in the kidney from a 38-week fetus (Figs. 5C, D) . A similar pattern, but with a patchy distribution, was noted in the kidney of a 7-week infant; however, staining in the kidney from an 8-month-old infant was completely negative for CDH17 expression.
DISCUSSION
This is the first study to investigate the utility of CDH17 in distinguishing MA from renal tumors with similar morphologic features.
Several IHC markers have been used to assist in the histologic diagnosis of MA. A panel of immunostains including WT-1, CD57, and AMACR has been shown to be helpful in distinguishing MA from its mimics, namely, e-WT and s-PRCC. 4, 7, 8 Our findings of high WT-1 sensitivity for e-WT and MA are in complete agreement with several previous reports. 4, 7, 8 WT-1 positivity is of great utility in ruling out s-PRCC but does not help in distinguishing MA from e-WT. CD57 is frequently expressed in MA, 1, 4, 7 although in our study CD57 was moderate to strongly positive in 35% of e-WT and 13% of s-PRCC. Similar to our findings, CD57 positivity was reported in 12.5% of WT, 8 in mature-appearing tubules of WT, 4 and in 70% of s-PRCC. 7 Although AMACR is considered to be a helpful marker for s-PRCC, 7,8 our results and previous studies have shown that AMACR is not entirely specific for s-PRCC, and AMACR immunoreactivity can be seen in 5% to 10% of MAs. 7,8 CDH17 appears to be a highly specific marker for MA, as in our series none of the cases of e-WT and s-PRCC was positive for CDH17.
CDH17, also known as liver-intestinal cadherin, is a member of the cadherin superfamily of calcium-dependent cell adhesion molecules. CDH17 is different from classic cadherins (such as E-cadherin) by its unique structural and functional features. 19 CDH17 protein consists of an extracellular region, containing 7 cadherin domains, and a transmembrane region; however, it lacks the conserved cytoplasmic domain. 27 Interestingly, CDH17 is structurally homologous to another member of the cadherin superfamily, cadherin 16, also known as kidney-specific cadherin (KSP-cadherin). 13, 14, 25 Because of this similarity, CDH17 and KSP-cadherin were termed as "7D-cadherins." 28 Expression of CDH17 appears to be tissue and species specific and is different between embryonal and adult tissues. CDH17 is mainly expressed in human fetal liver and gastrointestinal tract during embryogenesis. 29 Its expression is lost in normal adult human liver but maintained in normal adult human small and large intestine. CDH17 is not expressed in normal adult human renal tissue. 20 The zebrafish embryonic model is a valid system for studying renal development and function, as well as identification of genes important to the physiology and pathophysiology of the human kidney. Zebrafish cadherin 17 (cdh17) is closely related to human CDH17, possessing a 53% amino acid similarity. 24 The expression pattern of cdh17 is strikingly different from that of mammalian CDH17. In zebrafish, cdh17 is expressed specifically in the posterior portion of pronephric ducts during embryonic development, and knockdown of cdh17 disrupts the normal formation of the posterior portion of the pronephric ducts. 24 The embryonic pattern of cdh17 kidney expression is retained into adulthood zebrafish. Our study is the first to demonstrate the expression pattern of CDH17 during fetal development of human kidney. CDH17 appears to be differentially expressed during the late stages of fetal kidney development into early infancy but is lost in later infancy through adulthood. It would be of interest to examine the role of CDH17 in human nephrogenesis in further studies.
The histogenetic relationship of MA with nephrogenic rests, Wilms tumor, and the developing proximal tubule of the fetal kidney remains controversial. 1, 4, 30 Morphologically, MA is composed of cells that resemble nephrogenic rests, and this can explain many other terms that have been used to refer to MA, such as nephrogenic nephroma 31 and benign epithelial nephroblastoma. 32 This resemblance of MA to nephrogenic rests and Wilms tumor as well as similar expression of WT1 and CD57 between MA, WT, and nephrogenic rests may explain why MA is considered by some authors as a hyperdifferentiated benign end of the Wilms tumor spectrum. 4, 33 However, only 1 of 6 cases of nephrogenic rests was positive for CDH17 expression, and all WTs were negative in contrast to MA positivity in our study. At the genetic level, MA appears to be distinct from WT, as chromosomal alterations frequently present in the Wilms tumor have not been identified in MA, whereas BRAF V600E mutations have been described in approximately 90% of MAs. 34, 35 Other investigators provided IHC and ultrastructural evidence of similarity between MA and developing proximal tubular epithelium. The tumor cells of MA express the proximal tubule marker URO-2, 30 and, ultrastructurally, the tumor cells contain microvilli, 1 a characteristic feature of proximal tubular epithelium.
Morphologic, IHC, and ultrastructural similarities have been described between MA and 2 rare entities. One is embryonal hyperplasia of the Bowman capsular epithelium (EHBCE), found typically in patients with endstage renal failure who are being maintained on dialysis. 36 Another is designated as metanephric metaplasia of the Bowman capsular epithelium and is associated with widespread malignant neoplasms of various types. 37 De Silva et al 36 described a case of MA associated with EHBCE. The lesions showed many similarities on a morphologic, IHC, and ultrastructural basis, suggesting a possible relationship between these 2 entities. Bove et al 38 reported a case of EHBCE, which they called "diffuse metanephric adenoma," in a child who had been treated with dialysis since infancy for progressive renal failure. In this case, attempted suicide of the mother in the first trimester of pregnancy was thought to be responsible for the epithelial maturation defect present in this lesion. Persistent primitive epithelium at the junction of the glomerular space and proximal nephron was thought to be the most likely precursor of this proliferation, a hypothesis partly supported by electron microscopy. 38 In the current study, we found that MAs demonstrate a phenotype similar to the proximal tubules of the developing kidney in an area immediately adjacent to the glomerulus and in the parietal epithelium of the Bowman capsule. Our findings are in complete agreement with Bove and colleagues and support the histogenetic relationship of MA with the primitive epithelium at the junction of the glomerular space and proximal tubule.
In conclusion, CDH17 is a sensitive (81%) and highly specific (100%) marker for MA. CDH17 should be considered in the IHC panel for distinguishing MA from its mimics.
